Compare Ross Stores, Inc. (ROST) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ross Stores, Inc. vs BIO-TECHNE Corp — how do they compare? Ross Stores, Inc. trades at $226 (market cap $72.05B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Ross Stores, Inc. is far larger — about 6.3× BIO-TECHNE Corp's market cap, and Ross Stores, Inc. pays the higher dividend (0.79%). Which is the better fit depends on your goals — on Pluang, investors hold Ross Stores, Inc. for 48 Days and BIO-TECHNE Corp for 63 Days on average.
| ROST | TECH | |
|---|---|---|
Market Cap | $72.05B | $11.37B |
Volume | 1,674,861 | 3,153,511 |
Sector | Consumer Cyclical | Health |
52-Week High | $255.23 | $72.61 |
52-Week Low | $147.71 | $43.31 |
Typical Hold Time | 48 Days | 63 Days |
Enterprise Value | $72.50B | $11.40B |
Dividend Yield | 0.79% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ross Stores (ROST) trades at $225.20, up 0.44% today, showing strong fundamental performance with consistent earnings beats and robust profitability metrics including 42.63% ROE and 10.85% net margin. The stock faces technical headwinds with a bearish signal from moving averages, trading near support at $224. Recent news highlights store expansion initiatives and strong closeout supply benefits as the company captures value-conscious shoppers amid competitive retail pressures.
ROST presents a compelling investment case with analyst consensus pointing to 22% upside to the $274.14 price target, supported by strong earnings momentum and expanding margins. Key risks include retail competition, cost pressures, and macroeconomic sensitivity, but the company's value-focused strategy and operational discipline position it well for sustained growth.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
